Drug Insight: Aminosalicylates for the treatment of IBD

Research output: Contribution to journalReviewResearchpeer-review

Sulfasalazine and mesalazine (also known as mesalamine; 5-aminosalicylic acid) preparations have for many years been used for the treatment of IBD (i.e. ulcerative colitis and Crohn's disease), for both active disease and the control of remission. It has also been suggested that mesalazine is a chemoprophylactic agent that protects against the development of colorectal cancer. This Review focuses on the latest clinical evidence for the use of these aminosalicylates for the treatment of IBD, and concludes that sulfasalazine and mesalazine are useful for the treatment of both active and quiescent ulcerative colitis, whereas they have no clinical effect on either active or inactive Crohn's disease. Furthermore, evidence is lacking that mesalazine per se is a chemoprophylactic agent.

Original languageEnglish
JournalNature Clinical Practice Gastroenterology and Hepatology
Issue number3
Pages (from-to)160-170
Number of pages11
Publication statusPublished - 1 Mar 2007

ID: 218707483